Track topics on Twitter Track topics that are important to you
CytomX Therapeutics said today it will receive a $15 milestone payment from AbbVie for advancing a cancer-fighting Probody™ drug conjugate being developed by the companies into GLP toxicology studies toward filing an Investigational New Drug (IND) application next year. CX-2029 is a PDC designed to target CD71, also known as transferrin receptor 1 (TfR1), on tumor cells while sparing healthy cells by localizing the drug candidate’s activity primarily to cancer tissue. CD71 is highly and homogeneously expressed on many solid and blood tumor types. While that would make CD71 an ideal target for antibody drug conjugate strategies, the target is present on most normal cells—a challenge the companies say can be addressed by developing a therapeutic based on CytomX’s Probody platform. Probody therapeutics are designed to remain inactive until they are activated by proteases in the tumor microenvironment. According to CytomX, the therapeutics bind selectively to ...NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...